Nothing outstanding - we have a new mAb which failed against NSCLC:
AVEO Oncology announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer were presented at the 2012 Congress of the European Society for Medical Oncology. As previously reported, the study did not achieve its primary endpoint; however, the results presented at ESMO suggest that the addition of ficlatuzumab to gefitinib may be effective in select subsets of patients.
No comments:
Post a Comment